development of electrospun cellulose acetate /polyacrylonitrile /thymol /mg-metal organic framework composite nanofibers-based pipette-tip micro-solid phase extraction coupled with hplc-uv analysis for the quantification of anti-cancer drugs in biological fluids

In cancer therapy, pharmacological drugs are utilized to avoid the growth and proliferation of cancers or metastasis. in recent years, targeted cancer therapies have become one of the dominant generations of cancer treatment. however, in this type of cancer therapy, tumor-selective drugs have not been developed yet; therefore, normal cells can be targeted as well by these cytotoxic drugs. as a result, precision dosing is conducted as a crucial step prior to prescribing such drugs in order to optimize the plasma concentration of them, and subsequently their clinical effects without altering the overall health condition of a patient. quantifying trace levels of anti-cancer drug residues in biological fluids can be considered to provide valuable data for precision dosing [1]. in this study, a novel cellulose acetate /polyacrylonitrile /thymol /mg-metal organic framework composite electrospun nanofiber was developed as a sorbent in pipette-tip micro-solid phase extraction for the rapid and simultaneous extraction of three anti-cancer drugs, including letrozole, gefitinib, and riluzole in human biological fluids before separation and quantification by high-performance liquid chromatography-ultraviolet system. this nanosorbent was characterized by field emission scanning electron microscopy, energy-dispersive x-ray spectroscopy, x-ray diffraction, fourier transform infrared spectroscopy, and nitrogen adsorption-desorption analysis. incorporating polyacrylonitrile, thymol, and mg-mof into the cellulose acetate network confers appreciable properties to the sorbent, such as good mechanical stability, increased resistance versus water and chemicals, high porosity, and significant extraction ability. under the optimum conditions, the linearity was achieved in the range of 0.1-1500.0 µg l-1 for letrozole and gefitinib, and 0.25-1500.0 µg l-1 for riluzole with correlation coefficients ≥ 0.9996. low limit of detections (0.03-0.10 µg l-1), and limit of quantifications (0.10-0.33 µg l-1) with low relative standard deviations (≤6.6% for intra-day and ≤8.2% for inter-day), were also obtained. eventually, this method was successfully used to extract the mentioned analytes from the biological samples with acceptable relative recoveries (80.4-94.4%, relative standard deviations = 5.0-8.7%).